NCT00577356 Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer Status TERMINATED Phase PHASE2
NCT00577148 An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes Status TERMINATED Phase PHASE3
NCT00576823 Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology Status COMPLETED Phase PHASE3
NCT00576667 An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes Status TERMINATED Phase PHASE3
NCT00576368 An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice Status COMPLETED Phase PHASE4
NCT00575913 Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study Status COMPLETED Phase PHASE4
NCT00574275 Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer Status TERMINATED Phase PHASE3
NCT00566657 Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions Status COMPLETED Phase PHASE3
NCT00565448 Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents Status COMPLETED Phase PHASE2
NCT00565162 Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus Status COMPLETED Phase PHASE4
NCT00564187 Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice Status COMPLETED Phase PHASE4
NCT00563914 A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria Status COMPLETED Phase PHASE1/PHASE2
NCT00563771 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Status COMPLETED Phase PHASE4
NCT00562809 The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension Status COMPLETED Phase PHASE4